TScan Therapeutics Announces Strategic Reorganization, Pauses Phase 3 TSC-101

What Happened
TScan Therapeutics, Inc. (TCRX) filed an 8-K on September 2, 2026 announcing a strategic refocus to prioritize its in vivo solid tumor program and a pause of further enrollment in the Phase 3 ALLOHA-2 study of TSC-101. The company implemented a Strategic Reorganization that includes a workforce reduction of approximately 75%, effective September 2, 2026, and expects to substantially complete the reorganization by the end of Q4 2026. CFO Jason A. Amello and CMO Chrystal Louis were terminated effective September 2; CEO Gavin MacBeath assumed the principal financial and accounting officer duties.

Key Details

• Workforce & costs: ~75% workforce reduction; one-time employee-related charges expected of about $4.1 million (primarily pay continuation and benefits), most of which are cash expenditures. Company expects cumulative cost savings of $55.0 million through end of 2027.
• Pipeline shift: Two in vivo solid tumor candidates (targets PRAME and MAGE-A4) advanced into IND-enabling studies; company plans to share preclinical data in Q1 2027, file first IND in Q3 2027 and begin Phase 1 in Q4 2027.
• Heme program pause: Pausing further enrollment in ALLOHA-2 (TSC-101) due to capital constraints; trial had enrolled 7 patients on the treatment arm before the pause. Company will continue treating and following enrolled patients and seek partnerships.
• Nasdaq notice: On August 27, 2026 Nasdaq notified TScan that its stock closed below the $1.00 minimum bid price for 30 consecutive trading days; initial compliance period runs to February 23, 2027 (10-consecutive-day regain requirement), with a possible second 180-day period if conditions are met.
• Executive departures: Amello and Louis are entitled to 12 months of base salary (subject to executed releases) and COBRA premium coverage; Louis is also entitled to any unpaid target bonus for fiscal 2025 per her employment agreement.

Why It Matters

• Cost & runway: The reorganization is intended to extend runway (company says cash and securities as of June 30, 2026 should fund operations into Q4 2027) and save $55M through 2027, but the company will incur immediate severance costs (~$4.1M) and warns that actual charges may differ.
• Development focus: Moving resources to in vivo solid tumor programs (IND-enabling for PRAME and MAGE-A4) shifts near-term value drivers away from the heme-program Phase 3 trial; investors should track IND timelines and preclinical data milestones.
• Listing and governance risk: The Nasdaq minimum bid price deficiency creates a risk of transfer or potential delisting if compliance isn’t regained; the concurrent CFO departure and CEO taking on financial officer duties are material governance items investors should note.
• Clinical & partnership implications: Pausing ALLOHA-2 enrollment preserves resources but may slow or change the path for TSC-101 unless a partnership is found; the company will continue follow-up for enrolled patients.

Keywords: CEO, CFO, Nasdaq, delisting, Phase 3, IND-enabling, workforce reduction, cash runway, TSC-101, PRAME, MAGE-A4.